

May 14, 2026

National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (East) Mumbai – 400 051 Scrip Symbol: GALXYSURF	BSE Limited, Listing Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001 Scrip Code: 540935
---	---

Sub: Investor presentation on the Audited Financial Results for the quarter and year ended March 31, 2026.

Ref: Regulation 30 (2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/ Madam,

We are enclosing Investor Presentation on the Audited Financial Results for the quarter and year ended March 31, 2026.

The information is also hosted in announcement section on the website of the Company at www.galaxysurfactants.com.

We request you to take the same on record.

Yours faithfully,
For Galaxy Surfactants Limited

Niranjan Ketkar
Company Secretary
encl: as above

Galaxy Surfactants Ltd.

Regd. Office: C-49/2, TTC Industrial Area, Pawne, Navi Mumbai 400 703
P +91-22-39135500 **F** +91-39135554 **E** galaxy@galaxysurfactants.com
www.galaxysurfactants.com

CIN No. L39877MH1986PLC039877



Galaxy Surfactants Limited

**Result Presentation
May'26**

This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Galaxy Surfactants Limited** (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This Presentation contains certain forward looking statements concerning the Company’s future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company.



215+ Product Grades

Performance Surfactants: 47+
Specialty Care Products: 168+



Extensive R&D Capabilities

100+ Members
R&D Centre
Pilot Plant
Product Application Centre



7 Strategically Located Facilities with Inhouse Project Execution Capabilities

5 in India
1 in Egypt
1 in US



Serving 1,500+ Clients



Presence across 95+ countries



2,000+ Employees across all our Facilities

Q4 & FY26 Performance Highlights





Mr. K. Natarajan
Managing Director

“Our performance in Q4 and full year FY26 remained resilient despite a highly disrupted operating environment amid the ongoing West Asia conflict, which impacted global supply chains, logistics, and input costs.

EBITDA for Q4FY26 stood at ₹122 crore compared to ₹135 crore in Q4FY25, with EBITDA/MT at ₹ 20,113 versus ₹21,715 in the corresponding period last year, supported by effective pass-through of cost increases, an improved specialty product mix, strong performance of premium segments, and disciplined cost control.

India remained resilient with volumes growing by high single-digit on YoY in Q4, led by strong traction in Specialty Care Products and steady demand across Performance and non-Tier 1 segments, which helped offset earlier reformulation headwinds.

The AMET region witnessed a mid-teens YoY decline in volumes, primarily in the latter part of the quarter, due to logistics disruptions, raw material constraints, and cautious ordering by customers amid geopolitical uncertainty.

The Rest of the World recorded mixed trends, with volumes declining by high single digit YoY in Q4 due to shipment delays and elevated freight costs, while maintaining a 4% growth for the full-year. The Americas emerged as a relatively bright spot with sequential improvement in demand following tariff reversals and renewed traction in specialty products.

Further, while supply-side disruptions posed near-term challenges, the Company remains confident of navigating the environment through agile pricing actions, strong customer partnerships, continued focus on specialty growth, and expects sequential improvement in the coming quarters supported by a resilient business model and diversified global footprint.”

Key Developments

01

Consolidated Q4 volumes remained flat YoY, with **Specialty Care growing in high single digits on YoY** and offsetting high-single digits decline in Performance Surfactants

02

FY26 EBITDA remained dropped by 3% YoY to Rs 497 Cr vs Rs 510 Cr in FY25 and consequentially FY26 EBITDA / MT stood at Rs 19,357/MT vs FY25 at Rs 19,862/MT

03

India YoY Volume grew by high single digits on YoY basis driven by T2-T3 customers and Specialty Segment for Q4FY26

04

AMET volumes **declined in the mid teens** on YoY affected due to geopolitical disruption caused in West Asia for Q4FY26


05

ROW volumes **declined by high single digit** on YoY basis for Q4FY26

06

Fatty alcohol prices softened briefly but reversed as PKO/CPO gained on South East Asia seasonal supply tightness and front-loaded Q1 restocking, with Middle East geopolitical disruptions further keeping prices elevated due to higher freight/insurance costs and petchem raw material shortages

Segment Performance Highlights




Volume Summary	Q4FY26	FY26
Category wise		
Performance Surfactant	High single-digit decline	Mid single-digit decline
Specialty Care	High single-digit growth	High single-digit growth
Region wise		
India	High Single-digit growth	Low Single-digit growth
AMET	Mid-Teens decline	High Single-digit decline
ROW	High Single-digit decline	Low Single-digit growth

**Overall
Volume Flat
on YoY**


Consolidated Performance

Rs in cr


Total Revenue



EBITDA






PAT




Q4FY26

FY26




Revenue Performance

Category




■ Performance Surfactants
■ Specialty Care Products

Customer



■ MNC Customer
■ Regional Players
■ Local & Niche Player

Region wise Revenue



■ India
■ AMET
■ ROW

Consolidated Profit & Loss Statement

Particulars (Rs. In Crores)	Q4FY26	Q4FY25	Y-o-Y	Q3FY26	Q-o-Q	FY26	FY25	Y-o-Y
Net Revenue from Operations	1,314.7	1,144.9	14.8%	1,329.5	-1.1%	5,248.3	4,223.7	24.3%
Other Income	0.3	7.8		4.8		22.1	25.8	
Total Revenue	1,315.0	1,152.7	14.1%	1,334.3	-1.4%	5,270.4	4,249.5	24.0%
Cost of Material Consumed	975.1	808.4		998.5		3,917.7	2,885.6	
Employee's Benefits Expense	83.9	75.8		80.2		328.1	302.5	
Other Expenses	134.0	133.8		131.5		527.3	551.3	
EBITDA	121.9	134.7	-9.5%	124.2	-1.8%	497.4	510.0	-2.5%
EBITDA Margin	9.3%	11.7%		9.3%		9.4%	12.0%	
Depreciation	33.2	28.3		30.7		123.0	110.3	
EBIT	88.7	106.3	-16.6%	93.5	-5.1%	374.4	399.7	-6.3%
Finance cost	8.5	6.2		8.5		30.9	19.3	
PBT (Before Exceptional)	80.2	100.1	-19.9%	84.9	-5.6%	343.5	380.5	-9.7%
Exceptional Item	-	-		11.9 [#]		11.9 [#]	-	
PBT (After Exceptional)	80.2	100.1	-19.9%	73.0	9.8%	331.6	380.5	-12.8%
Tax expense	17.8	24.3		14.1		64.3	75.5	
PAT	62.4	75.9	-17.7%	59.0	5.9%	267.4	304.9	-12.3%
PAT Margin	1.4%	2.1%		1.1%		1.2%	1.8%	
Other Comprehensive Income	71.8	-7.1		14.4		126.8	20.2	
Total Comprehensive Income	134.3	68.8	95.3%	73.4	83.0%	394.2	325.1	21.2%
EPS	17.60*	21.40*		16.63*		75.41	86.00	

Fatty Alcohol prices in this quarter increased to an average price of \$ 2,751/MT vs Q3 when it stood at \$ 2,588/MT. The same was \$ 2,494/MT in Q4FY25

Consolidated Balance Sheet

Particulars (Rs. In Crores)	Mar'26	Mar'25
ASSETS		
Property, Plant and Equipment	982.5	839.8
Right-of-use assets	182.9	184.3
Capital work-in-progress	181.4	261.9
Goodwill	3.4	3.1
Other Intangible Assets	4.9	3.3
Financial Assets		
(i) Investments	1.0	
(ii) Loans	1.9	1.8
(iii) Other financial assets	18.6	21.7
Deferred Tax Assets (Net)	9.1	12.1
Income Tax Assets (Net)	14.1	8.2
Other Non-current assets	31.6	32.5
Total Non-Current Assets	1,431.3	1,368.5
Current Assets		
Inventories	793.7	723.9
Financial Assets		
(i) Investments	472.6	298.5
(ii) Trade receivables	750.4	686.5
(iii) Cash and cash equivalents	109.1	193.4
(iv) Bank Balances other than cash and cash equivalents	165.8	22.4
(v) Loans	1.1	0.9
(vi) Other Financial Assets	7.7	10.0
Other Current Assets	142.4	157.9
Total Current Assets	2,442.8	2,093.6
TOTAL ASSETS	3,874.2	3,462.1

Particulars (Rs. In Crores)	Mar'26	Mar'25
EQUITY AND LIABILITIES		
EQUITY		
Equity Share Capital	35.5	35.5
Other Equity	2,709.4	2,327.1
Total Shareholders Fund	2,744.8	2,362.5
Non-Current Liabilities		
Financial Liabilities		
(i) Borrowings	5.7	17.1
(ii) Lease Liabilities	57.7	58.8
(iii) Other Financial Liabilities	0.3	0.3
Provisions	14.7	10.0
Deferred Tax Liabilities (Net)	31.4	31.8
Other Non-current Liabilities	3.1	3.2
Total Non-Current Liabilities	112.9	121.2
Current Liabilities		
Financial Liabilities		
(i) Borrowings	158.8	124.7
(ii) Trade Payables	650.9	620.0
(iii) Lease Liabilities	13.3	9.6
(iv) Other Financial Liabilities	15.7	26.4
Other Current Liabilities	163.8	183.4
Provisions	9.2	8.0
Current Tax Liabilities (Net)	4.8	6.2
Total Current Liabilities	1,016.4	978.3
TOTAL EQUITY & LIABILITIES	3,874.2	3,462.1

Consolidated Cashflow Statement

Particulars (Rs. In Crores)	FY26	FY25
Cash Flow From Operating Activities :		
Profit After Tax	267.4	304.9
Operating Profit before working Capital changes	469.3	484.5
Net cash flows generated from/(used) in Operating Activities (A)	332.7	420.5
Net cash flows generated from/(used) in Investing Activities (B)	-377.6	-294.6
Net cash flows generated from/(used) in Financing Activities (C)	-51.0	-157.3
Net Increase/(Decrease) in cash and cash equivalents (A+B+C)	-95.9	-31.4
Opening cash and cash equivalents	193.4	220.5
Effects of exchange rate changes on the balance of cash and cash equivalents held in foreign currencies	11.7	4.3
Closing cash and cash equivalents	109.1	193.4

Standalone Profit & Loss Statement

Particulars (Rs. In Crores)	Q4FY26	Q4FY25	Y-o-Y	Q3FY26	Q-o-Q	FY26	FY25	Y-o-Y
Net Revenue from Operations	928.3	814.3	14.0%	867.7	7.0%	3,589.1	3,001.3	19.6%
Other Income	6.2	6.7		3.9		29.6	26.5	
Total Revenue	934.5	820.9	13.8%	871.6	7.2%	3,618.7	3,027.7	19.5%
Cost of Material Consumed	712.6	608.2		679.2		2,782.3	2,170.2	
Employee's Benefits Expense	47.3	40.6		43.4		181.6	171.1	
Other Expenses	88.6	90.5		83.3		337.9	377.9	
EBITDA	86.0	81.7	5.2%	65.7	30.9%	316.8	308.5	2.7%
EBITDA Margin	9.2%	10.0%		7.5%		8.8%	10.2%	
Depreciation	20.7	17.1		18.7		75.4	67.2	
EBIT	65.4	64.7	1.1%	46.9	39.2%	241.5	241.4	0.0%
Finance cost	7.8	5.3		7.8		27.6	16.6	
PBT (Before Exceptional)	57.6	59.3	-3.0%	39.2	46.8%	213.9	224.8	-4.9%
Exceptional Item	-	-		11.9 [#]		11.9 [#]	-	
PBT (After Exceptional)	57.6	59.3	-3.0%	27.3	110.7%	202.0	224.8	-10.1%
Tax expense	13.5	15.3		7.6		49.9	51.0	
PAT	44.1	44.0	0.1%	19.7	123.7%	152.0	173.8	-12.5%
PAT Margin	1.4%	1.9%		0.9%		1.4%	1.7%	
Other Comprehensive Income	3.4	-3.4		-0.1		3.0	-2.8	
Total Comprehensive Income	47.5	40.7	16.9%	19.6	142.9%	155.1	171.0	-9.3%
EPS	12.44*	12.42*		5.56*		42.88	49.03	

Standalone Balance Sheet

Particulars (Rs. In Crores)	Mar'26	Mar'25
ASSETS		
Property, Plant and Equipment	690.3	553.5
Right-of-use assets	145.4	145.4
Capital work-in-progress	176.7	253.9
Other Intangible Assets	4.5	3.1
Financial Assets		
(i) Investments	126.8	117.8
(ii) Loans	1.9	1.8
(iii) Other financial assets	15.4	18.6
Income Tax Assets (Net)	8.1	8.2
Other Non-current assets	26.0	29.1
Total Non-Current Assets	1,195.1	1,131.3
Current Assets		
Inventories	523.7	437.6
Financial Assets		
(i) Investments	87.7	95.5
(ii) Trade Receivables	576.9	492.8
(iii) Cash and Cash Equivalents	5.3	9.0
(iv) Bank Balances other than Cash and Cash Equivalents	0.7	13.9
(v) Loans	1.1	0.9
(vi) Other Financial Assets	14.7	11.1
Other Current Assets	63.2	132.7
Total Current Assets	1,273.3	1,193.4
TOTAL ASSETS	2,468.4	2,324.8

Particulars (Rs. In Crores)	Mar'26	Mar'25
EQUITY AND LIABILITIES		
EQUITY		
Equity Share Capital	35.5	35.5
Other Equity	1,542.5	1,399.3
Total Shareholders Fund	1,578.0	1,434.7
Non-Current Liabilities		
Financial Liabilities		
(i) Borrowings	5.7	17.1
(ii) Lease Liabilities	19.0	18.8
(iii) Other Financial Liabilities	0.3	0.3
Provisions	14.7	10.0
Deferred Tax Liabilities (Net)	36.4	34.2
Other non-current liabilities	3.1	3.2
Total Non-Current Liabilities	79.3	83.6
Current Liabilities		
Financial Liabilities		
(i) Borrowings	158.8	119.8
(ii) Trade Payables	557.6	512.4
(iii) Lease Liabilities	7.1	4.9
(iv) Other Financial Liabilities	15.8	21.6
Other Current Liabilities	58.6	137.8
Provisions	8.8	6.5
Current Tax Liabilities (Net)	4.6	3.5
Total Current Liabilities	811.1	806.5
TOTAL EQUITY & LIABILITIES	2,468.4	2,324.8



Standalone Cashflow Statement

Particulars (Rs. In Crores)	FY26	FY25
Cash Flow From Operating Activities :		
Profit After Tax	152.0	173.8
Operating Profit before working Capital changes	272.1	282.7
Net cash flows generated from/(used) in Operating Activities (A)	94.9	295.5
Net cash flows generated from/(used) in Investing Activities (B)	-69.3	-164.8
Net cash flows generated from/(used) in Financing Activities (C)	-29.1	-143.6
Net Increase/(Decrease) in cash and cash equivalents (A+B+C)	-3.5	-13.0
Opening cash and cash equivalents	9.0	21.9
Effects of exchange rate changes on the balance of cash and cash equivalents held in foreign currencies	-0.1	0.0
Closing cash and cash equivalents	5.3	8.9

Managing Volatility in Raw Material Prices and Currency...

Fatty Alcohol Prices (USD / MT)

INR / USD Prices



... through Robust Risk Management Practices



Thank You

Company



CIN No: L39877MH1986PLC039877

Mr. Ruchir Soni

Email: Ruchir.Soni@galaxysurfactants.com

www.galaxysurfactants.com

Investor Relations Advisors :

SGA Strategic Growth Advisors

CIN - U74140MH2010PTC204285

Mr. Mandar Chavan / Mr. Rahul Agarwal

mandar.chavan@sgapl.net /

rahul.agarwal@sgapl.net

+91 96993 82195 / +91 98214 38864

www.sgapl.net